July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Posterior Vitreous Detachment Associated with Retinoblastoma and Intravitreal Melphalan Injections for Vitreous Seeding
Author Affiliations & Notes
  • Ramon Lee
    USC Roski Eye Institute, Los Angeles, California, United States
  • Luv Patel
    USC Roski Eye Institute, Los Angeles, California, United States
  • Jonathan W Kim
    USC Roski Eye Institute, Los Angeles, California, United States
    Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California, United States
  • Jesse L Berry
    USC Roski Eye Institute, Los Angeles, California, United States
    Ophthalmology, Children's Hospital Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Ramon Lee, None; Luv Patel, None; Jonathan Kim, None; Jesse Berry, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1645. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ramon Lee, Luv Patel, Jonathan W Kim, Jesse L Berry; Posterior Vitreous Detachment Associated with Retinoblastoma and Intravitreal Melphalan Injections for Vitreous Seeding. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1645.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This 8 year retrospective review aims to report the incidence of posterior vitreous detachment (PVD) with B-scan ultrasonography at diagnosis of retinoblastoma and in the setting of intravitreal melphalan injection for vitreous seeding and correlate the findings to outcomes of posterior segment toxicity and globe salvage.

Methods : Eligible eyes of patients were diagnosed with retinoblastoma between January 2010 to July 2017 at a single institution and were evaluated with B-scan ultrasonography. Overall, 116 eyes of 82 patients were included. The primary outcome measures were incidence of PVD at time of diagnosis, incidence of PVD associated with intravitreal melphalan injection, and associations of PVD with posterior segment toxicity and globe salvage with intravitreal melphalan injection.

Results : At the time of diagnosis, 62 eyes underwent B-scan ultrasonography with 37% (23/62 eyes) with PVD, 37% (23/62 eyes) without PVD, and 26% (16/62 eyes) with large tumors that precluded the evaluation of PVD. Incidence of PVD at diagnosis was higher within Group D and Group E eyes with 52% (16/31 eyes) and 38% (6/16 eyes), respectively. Of the eyes included, 31 eyes received intravitreal melphalan injection. Three eyes (of 14, 21%) had PVD induced by intravitreal melphalan injection. The incidence of posterior segment toxicity was similar between eyes with and without PVD that received intravitreal melphalan injections with 54% (7/13 eyes) and 50% (7/14 eyes), respectively (p = 0.8416). The incidence of globe salvage with eyes with and without PVD that received intravitreal melphalan injections was 77% (10/13 eyes) and 93% (13/14 eyes), respectively (p = 2.442).

Conclusions : PVD is a common finding at diagnosis with retinoblastoma and a higher incidence of PVD was found within Group D and Group E eyes. The presence or absence of PVD did not show statistically significant association with increased incidence of posterior segment toxicity or globe salvage in eyes that were treated with intravitreal melphalan for vitreous seeding.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×